Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Radiochemotherapy in Unresectable Esophageal Cancer (ARION)
NCT03777813Phase 2Completed
- Sponsor
- Unicancer
- Start
- Dec 2018
- Primary completion
- May 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in esophageal cancer, sponsored by Unicancer. Started Dec 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03777813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03777813.